Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of
patients worldwide. Despite all the efforts to understand its pathogenesis and develop new …

Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of
monoclonal plasma cells localized within the bone marrow. Bone disease with associated …

Background Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence
cases leukaemia, lymphoma, and multiple myeloma in 2020. Identifying its geographical …

Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled
proliferation of plasma cells in the bone marrow. MM patients with aggressive progression …

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …

Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of
hematologic malignancies. There is limited epidemiological evidence regarding the long …

Simple Summary Bispecific antibodies (BsAbs) provide a new mode of targeting multiple
myeloma (MM) plasma cells (PCs), basing their action on the activation and redirection of …

Multiple myeloma is an incurable malignancy of clonal plasma cells. Various diagnostic
methods are used in parallel to accurately determine stage and severity of the disease …

Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of
immunoglobulin-secreting clonal plasma cells at the bone marrow (BM). The interaction …

The introduction of high-dose therapy in the 1990s as well as the development of drugs such
as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive …